Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
RARE
$51.20
Ultragenyx Pharmaceu
($.37)
(.72%)
RARE
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus: ($1.49)
Revenue: $94.66 Mil
Thursday
Oct 27
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, July 28, 2022
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
What do you expect when RARE reports earnings?
Beat
Meet
Miss
Where is RARE's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$53.67
$53.01
$52.29
$51.64
Support
$50.92
$50.26
$49.54
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.
Peers
Vertex Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
Johnson & Johnson
Regeneron Pharmaceuticals
Eli Lilly
BioMarin Pharmaceutical
Pfizer
Array Technologies
Catalent
Expectations
›
Ultragenyx Pharmaceu